GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunocore Holdings PLC (STU:6YG) » Definitions » Cash Flow from Others

Immunocore Holdings (STU:6YG) Cash Flow from Others : €-13.7 Mil (TTM As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Immunocore Holdings Cash Flow from Others?

Immunocore Holdings's cash flow from others for the three months ended in Mar. 2025 was €-6.8 Mil. Its cash flow from others for the trailing twelve months (TTM) ended in Mar. 2025 was €-13.7 Mil.


Immunocore Holdings Cash Flow from Others Historical Data

The historical data trend for Immunocore Holdings's Cash Flow from Others can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunocore Holdings Cash Flow from Others Chart

Immunocore Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Others
Get a 7-Day Free Trial 42.36 13.36 -6.79 14.57 -6.09

Immunocore Holdings Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Flow from Others Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.60 -2.91 -11.91 7.86 -6.77

Immunocore Holdings Cash Flow from Others Calculation

Cash Flow from Others for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-13.7 Mil.

Immunocore Holdings Cash Flow from Others Related Terms

Thank you for viewing the detailed overview of Immunocore Holdings's Cash Flow from Others provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunocore Holdings Business Description

Traded in Other Exchanges
Address
92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Immunocore Holdings Headlines

No Headlines